Guardant Silent on TMB Plans, but Study Adds Evidence for Immunotherapy Prediction in Blood

NEW YORK (GenomeWeb) – A new study this month has added to the so-far scant data available on the ability of Guardant Health’s Guardant360 assay to predict responsiveness to immunotherapy using a blood-based signal to infer how highly mutated a patient’s cancer is.

Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Be the first to comment

Leave a Reply

Your email address will not be published.


*